Ali Arsalan Akbar, Avilés Elescano Denisse, Grover Davinder S
Anne Burnett Marion School of Medicine, Texas Christian University, Fort Worth, TX, USA.
Universidad San Martin de Porres (USMP), Lima, Peru.
Clin Ophthalmol. 2024 May 15;18:1371-1377. doi: 10.2147/OPTH.S450220. eCollection 2024.
To characterize clinical outcomes following a single administration of bimatoprost SR in eyes with glaucoma in a real-world setting implanted at the slit-lamp.
Tertiary care Glaucoma practice, Glaucoma Associates of Texas, Dallas, Texas.
Retrospective interventional case series.
Data were analyzed from consecutive patients receiving a single bimatoprost SR implant from the time of its approval to the time of data collection. All eyes were implanted at the slit-lamp. Eyes with less than 1 month of follow-up were excluded. The primary outcome was median time to next intraocular pressure (IOP)-lowering intervention. Mean IOP and medication use, and changes from baseline, were also assessed through 12 months of follow-up.
Overall 129 eyes of 81 patients were analyzed. Following bimatoprost SR administration (replacing a topical prostaglandin analogue [PGA] in most eyes), the median survival time without any further IOP-lowering interventions was between 6-9 months. Mean IOP remained unchanged from baseline at month 1 (consistent with switch from topical to intracameral PGA therapy) and began to rise at month 3. At month 12, 40.5% of eyes (52 eyes) remained intervention-free, mean medication reduction was 0.5 medications per eye, and 27.8% of eyes (36 eyes) were medication-free. Adverse events were uncommon and most were transient and resolved with or without intervention.
This real-world analysis of bimatoprost SR use for glaucoma therapy complements Phase 3 study findings and demonstrates that the implant can safely provide medication reduction through 6 months in most eyes and through 12 months in almost 40% of eyes.
在实际临床环境中，对在裂隙灯下植入的青光眼患者单次给予比马前列素缓释剂（bimatoprost SR）后的临床结果进行特征描述。
德克萨斯州达拉斯市德克萨斯青光眼协会三级医疗青光眼诊所。
回顾性干预病例系列研究。
分析从比马前列素缓释剂获批至数据收集期间连续接受单次植入的患者的数据。所有眼睛均在裂隙灯下植入。随访时间少于1个月的眼睛被排除。主要结局是至下一次降低眼压（IOP）干预的中位时间。还通过12个月的随访评估了平均眼压、药物使用情况以及与基线相比的变化。
共分析了81例患者的129只眼睛。给予比马前列素缓释剂后（大多数眼睛停用了局部前列腺素类似物[PGA]），在没有任何进一步降低眼压干预的情况下，中位生存时间为6 - 9个月。第1个月时平均眼压与基线相比无变化（与从局部PGA治疗转换为前房内PGA治疗一致），并在第3个月开始上升。在第12个月时，40.5%的眼睛（52只）无需干预，平均每只眼睛减少使用0.5种药物，27.8%的眼睛（36只）无需使用药物。不良事件不常见，大多数是短暂的，无论是否干预均可缓解。
这项对比马前列素缓释剂用于青光眼治疗的实际临床分析补充了3期研究结果，并表明该植入物可安全地使大多数眼睛在6个月内减少药物使用，近40%的眼睛在12个月内减少药物使用。
